Attendee Testimonials

Hear What Previous Attendees Have to Say About the mRNA-Based Therapeutics Summit Europe

Eun-Jung Lee, Principal Scientist, Biologics Discovery Team, Yuhan Corporation

“Overall great experience, a lot was learned, would definitely recommend and attend again.”

Eun-Jung Lee,
Principal Scientist, Biologics Discovery Team, Yuhan Corporation

Yuhan_Logo_(ENG).svg
Roland Pach , Global Expert Cell- & Gene Therapy Analytics CMC, Roche

“The summit gave a fantastic insight into the exiting mRNA world”

Roland Pach,
Global Expert Cell- & Gene Therapy Analytics CMC, Roche

Roche_Logo.svg (1)
Kenny Simmen, Ph.D Vice President, Scientific Innovation, Infectious Diseases and Vaccines

“An excellent 2 days summary of the latest developments in this fast moving field.”

Kenny Simmen,
Ph.D Vice President, Scientific Innovation, Infectious Diseases and Vaccines, Johnson & Johnson

2560px-Johnson_and_Johnson_Logo.svg (1)
Andreas Kuhn

“With the recent progress in mRNA therapeutics and vaccines, this will be a great opportunity to learn about the latest developments and connect with the RNA community, especially the European one.”

Andreas Kuhn,
Senior VP - RNA Biochemistry & Manufacturing, BioNTech

BioNTech_logo.svg
moderna-default

“As mRNA therapies are in their infancy. It is enormously important to bring together scientists from all over the world to discuss novel approaches and applications of mRNA in order to further the field. I view this meeting as an important event to build bridges necessary for the betterment of mRNA- based science.”

Patrick Finn,
Senior Director - Rare Diseases, Moderna

Untitled design (72)

“I look forward to networking with experts in this emerging and exiting field as well as the opportunity to learn more about developments and innovation in mRNA technology.”

Lucia Lapazio,
Group Lead mRNA, Sanofi

Dariush Mohammadyani

“It is a great pleasure to be a speaker in this event among other well-known speakers. While mRNA vaccines are in use now, mRNA therapeutics still have a lot of unleashed potentials. We are speaking about the bright future of mRNA therapeutics.”

Dariush Mohammadyani,
Senior Scientist, Johnson & Johnson

2560px-Johnson_and_Johnson_Logo.svg (1)
Marcus Wilhelmsson

“It will be very inspiring to share our latest results with the leaders in industry as well as academia, to get valuable feedback on how we can help facilitate investigations of mRNA uptake processes, and what we need to develop even further. Moreover, it will be invaluable to listen to novel ideas and results by leaders in the field and in that way get new ideas on how industry and academia can work together towards a general, efficient and safe delivery method for RNA-based therapeutics.”

Marcus Wilhelmsson,
Professor, Chalmers University of Technology

chalmers-university-of-technology-logo-freelogovectors.net_